<DOC>
	<DOCNO>NCT02578121</DOCNO>
	<brief_summary>The purpose study determine efficacy Ixazomib combine Pomalidomide Dexamethasone , term overall response rate subject relapse Multiple Myeloma</brief_summary>
	<brief_title>UARK 2015-03 A Phase II Trial Novel Proteasome/IMiD Combination</brief_title>
	<detailed_description>This single arm , Phase II study examine efficacy safety novel Proteasome/IMiD combination Ixazomib 4mg day 1 , 8 , 15 , Pomalidomide 4 mg day 1-21 , Dexamethasone 20 mg day 1 , 8 , 15 , 22 28 day cycle , relapse patient . The long term aim develop backbone regimen future novel target treatment may add part personalize medicine approach .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study : Male female patient 18 year old . Voluntary write consent must give performance study relate procedure part standard medical care , understand consent may withdraw patient time without prejudice future medical care . Female patient : Are postmenopausal least 1 year screen visit , OR Are surgically sterile , OR If childbearing potential , agree practice 2 effective method contraception , time , time signing informed consent form 90 day last dose study drug , AND Agree practice true abstinence line prefer usual lifestyle subject . ( Periodic abstinence [ eg , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method contraception . ) Male patient , even surgically sterilize ( ie , status postvasectomy ) , must agree one following : Agree practice effective barrier contraception entire study treatment period 90 day last dose study drug , OR Agree practice true abstinence line prefer usual lifestyle subject . ( Periodic abstinence ( eg , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method contraception . ) Patients must diagnosis relapsed and/or refractory multiple myeloma must receive least one line prior therapy . Patients must least 14 day beyond last multiple myeloma therapy recover acute toxicity prior therapy measure CTCAE ( Version 4.0 ) Patients must life expectancy least 3 month . Eastern Cooperative Oncology Group ( ECOG ) performance status and/or performance status 0 , 1 , 2 . Patients must meet follow clinical laboratory criterion : Absolute neutrophil count ( ANC ) &gt; 1,000/mm3 platelet count &gt; 50,000/mm3 . Platelet transfusion help patient meet eligibility criterion allow within 3 day study enrollment . Total bilirubin &lt; 1.5 x upper limit normal range ( ULN ) . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 3 x ULN . Calculated creatinine clearance &gt; 30 mL/min ( see APPENDIX C CockcroftGault Equation ) . , Patients meet follow exclusion criterion enrol study : Female patient lactate positive serum pregnancy test screening period . Failure fully recover ( ie , &lt; Grade 1 toxicity ) reversible effect prior chemotherapy . Major surgery within 14 day enrollment . Radiotherapy within 14 day enrollment . If involved field small , 7 day consider sufficient interval . Central nervous system involvement . Infection require systemic antibiotic therapy serious infection within 14 day study enrollment . Evidence current uncontrolled cardiovascular condition , include uncontrolled hypertension , uncontrolled cardiac arrhythmia , symptomatic congestive heart failure , unstable angina , myocardial infarction within past 6 month . Ongoing active systemic infection , active hepatitis B C virus infection , know human immunodeficiency virus ( HIV ) positive . Any serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol . Known allergy study medication , analogue , excipients various formulation agent . Known GI disease GI procedure could interfere oral absorption tolerance oral medication include difficulty swallowing . Diagnosed treat another malignancy within 2 year study enrollment previously diagnose another malignancy evidence residual disease . Patients nonmelanoma skin cancer carcinoma situ type exclude undergone complete resection . Patient &gt; Grade 3 peripheral neuropathy , Grade 2 pain clinical examination screen period . Participation clinical trial , include investigational agent include trial , within 21 day start trial throughout duration trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Response Rate</keyword>
	<keyword>Progression free</keyword>
</DOC>